Fenofibrate and Valcyte drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Fenofibrate (fenofibrate) and Valcyte (valganciclovir hydrochloride). Common drug interactions include dyspnoea among females and chronic kidney disease among males.

The phase IV clinical study analyzes what interactions people have when they take Fenofibrate and Valcyte. It is created by eHealthMe based on reports of 24 people who take the same drugs from the FDA, and is updated regularly.

What is Fenofibrate?

Fenofibrate has active ingredients of fenofibrate. It is often used in high blood cholesterol. eHealthMe is studying from 40,455 Fenofibrate users. Check the latest studies of Fenofibrate.

What is Valcyte?

Valcyte has active ingredients of valganciclovir hydrochloride. It is often used in cmv - immunocompromised host. eHealthMe is studying from 6,409 Valcyte users. Check the latest studies of Valcyte.



On Mar, 29, 2026

24 people who take Fenofibrate and Valcyte together, and have interactions are studied.

Fenofibrate and Valcyte drug interactions.

What are the common drug interactions of Fenofibrate and Valcyte, by gender? *:

female:

  1. Dyspnoea (difficult or laboured respiration)
  2. Encephalopathy (functioning of the brain is affected by some agent or condition)
  3. Fall
  4. Renal impairment (severely reduced kidney function)
  5. Accelerated hypertension (significant hypertension)
  6. Acute respiratory failure
  7. Alopecia (absence of hair from areas of the body)
  8. Angina pectoris (chest pain due to ischemia of the heart muscle)
  9. Ankle fracture
  10. Arrhythmia (irregular heartbeat)

male:

  1. Chronic kidney disease
  2. Emotional distress
  3. Nephropathy (damage to or disease of a kidney)
  4. Osteoporosis (bones weak and more likely to break)
  5. Pneumonia
  6. Thrombosis (formation of a blood clot inside a blood vessel)
  7. Arthralgia (joint pain)
  8. Back pain
  9. Confusional state
  10. Death

What are the common drug interactions of Fenofibrate and Valcyte, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Confusional state
  2. Death
  3. Delusion (a false belief or opinion)
  4. Disorientation (disability in which the senses of time, direction, and recognition of people and places)
  5. Disturbance in attention
  6. Drug screen positive
  7. Dyspnoea (difficult or laboured respiration)
  8. Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
  9. Paranoia (psychotic disorder characterized by delusions of persecution with or without grandeur)
  10. White blood cell count increased

40-49:

  1. Chronic kidney disease
  2. Emotional distress
  3. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  4. Pain
  5. Renal failure (kidney dysfunction)
  6. Accelerated hypertension (significant hypertension)
  7. Acute respiratory failure
  8. Alopecia (absence of hair from areas of the body)
  9. Angina pectoris (chest pain due to ischemia of the heart muscle)
  10. Arrhythmia (irregular heartbeat)

50-59:

  1. Chronic kidney disease
  2. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  3. Sepsis (a severe blood infection that can lead to organ failure and death)
  4. Wound
  5. Nephrogenic anaemia (anaemia due to kidney disease)
  6. Glomerulonephritis membranous (nephritis with inflammation of the capillary loops in the renal glomeruli)
  7. Haematoma (collection of blood outside the blood vessels)
  8. Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood)
  9. Hypoparathyroidism secondary (inadequate secretion of parathyroid hormone resulting in abnormally low levels of calcium in the blood -due to another disease)
  10. Immunodeficiency

60+:

  1. Emotional distress
  2. Encephalopathy (functioning of the brain is affected by some agent or condition)
  3. Facial bones fracture (bone fracture of face)
  4. Fall
  5. Hand fracture
  6. Influenza
  7. Laceration (tearing of soft body tissue)
  8. Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung)
  9. Rib fracture
  10. Scapula fracture (a fracture of the scapula, the shoulder blade)

What are the existing conditions these people have? *

  1. Pain: 9 people, 37.50%
  2. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 7 people, 29.17%
  3. High Blood Pressure: 5 people, 20.83%
  4. Multiple Myeloma (cancer of the plasma cells): 4 people, 16.67%
  5. Constipation: 4 people, 16.67%
  6. Nausea (feeling of having an urge to vomit): 4 people, 16.67%
  7. Hiv Infection: 4 people, 16.67%
  8. Haemolytic Uraemic Syndrome (blood clotting disease caused by e. coli infection, birth control pills, pneumonia, medications, and more): 3 people, 12.50%
  9. Immunodeficiency Disorders: 2 people, 8.33%
  10. Infection: 2 people, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Fenofibrate and Valcyte?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Fenofibrate and Valcyte:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Fenofibrate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Valcyte:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Fenofibrate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Valcyte and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on fenofibrate and valganciclovir hydrochloride (the active ingredients of Fenofibrate and Valcyte, respectively), and Fenofibrate and Valcyte (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: